Back to Search
Start Over
Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review
- Source :
- Addi. Archivo Digital para la Docencia y la Investigación, instname, European Neuropsychopharmacology, Reininghaus, E Z, Manchia, M, Dalkner, N, Bonkat, N, Squassina, A, Hodl, I, Vieta, E, Reif, A, Hajek, T, Landén, M, Correll, C U, Scott, J, Etain, B, Rietschel, M, Bergink, V, Martinez-Cengotitabengoa, M, Kessing, L V, Fagiolini, A, Bauer, M, Goodwin, G, Gonzalez-Pinto, A, Kupka, R W, Schulze, T G, Lagerberg, T V, Yildiz, A, Henry, C, Morken, G, Ritter, P, Nieslen, R E, Licht, R W, Bechdolf, A, Andreassen, O A & Fellendorf, F T 2022, ' Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic-a systematic review ', European Neuropsychopharmacology, vol. 54, pp. 90-99 . https://doi.org/10.1016/j.euroneuro.2021.09.001, European Neuropsychopharmacology, 2022, 54, pp.90-99. ⟨10.1016/j.euroneuro.2021.09.001⟩
- Publication Year :
- 2022
-
Abstract
- Bipolar disorder (BD) might be associated with higher infection rates of coronavirus disease (COVID-19) which in turn could result in worsening the clinical course and outcome. This may be due to a high prevalence of somatic comorbidities and an increased risk of delays in and poorer treatment of somatic disease in patients with severe mental illness in general. Vaccination is the most important public health intervention to tackle the ongoing pandemic. We undertook a systematic review regarding the data on vaccinations in individuals with BD. Proportion of prevalence rates, efficacy and specific side effects of vaccinations and in individuals with BD were searched. Results show that only five studies have investigated vaccinations in individuals with BD, which substantially limits the interpretation of overall findings. Studies on antibody production after vaccinations in BD are very limited and results are inconsistent. Also, the evidence-based science on side effects of vaccinations in individuals with BD so far is poor. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
- Subjects :
- MESH: Pandemics
medicine.medical_specialty
Pediatrics
Bipolar disorder
[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health
Prevalence
Disease
infectious diseases
Communicable Diseases
Article
MESH: Communicable Disease Control
systematic review
MESH: Bipolar Disorder
Intervention (counseling)
Pandemic
MESH: COVID-19
Medicine
Humans
MESH: SARS-CoV-2
Pharmacology (medical)
Pandemics
Biological Psychiatry
bipolar disorder
Pharmacology
Vaccines
MESH: Humans
business.industry
SARS-CoV-2
Public health
Vaccination
COVID-19
vaccination
Mental illness
medicine.disease
MESH: Vaccines
Psychiatry and Mental health
Neurology
[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health
Communicable Disease Control
MESH: Communicable Diseases
Systematic review
Infectious diseases
Neurology (clinical)
business
Subjects
Details
- Language :
- English
- ISSN :
- 0924977X and 18737862
- Database :
- OpenAIRE
- Journal :
- Addi. Archivo Digital para la Docencia y la Investigación, instname, European Neuropsychopharmacology, Reininghaus, E Z, Manchia, M, Dalkner, N, Bonkat, N, Squassina, A, Hodl, I, Vieta, E, Reif, A, Hajek, T, Landén, M, Correll, C U, Scott, J, Etain, B, Rietschel, M, Bergink, V, Martinez-Cengotitabengoa, M, Kessing, L V, Fagiolini, A, Bauer, M, Goodwin, G, Gonzalez-Pinto, A, Kupka, R W, Schulze, T G, Lagerberg, T V, Yildiz, A, Henry, C, Morken, G, Ritter, P, Nieslen, R E, Licht, R W, Bechdolf, A, Andreassen, O A & Fellendorf, F T 2022, ' Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic-a systematic review ', European Neuropsychopharmacology, vol. 54, pp. 90-99 . https://doi.org/10.1016/j.euroneuro.2021.09.001, European Neuropsychopharmacology, 2022, 54, pp.90-99. ⟨10.1016/j.euroneuro.2021.09.001⟩
- Accession number :
- edsair.doi.dedup.....34f359971aae139b464cee1385604f72
- Full Text :
- https://doi.org/10.1016/j.euroneuro.2021.09.001